STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
AI Summary
AbbVie is set to acquire Apogee Therapeutics, a company developing an experimental drug for atopic dermatitis, for nearly $11 billion. This deal underscores continued acquisition activity in the pharmaceutical sector.
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.